CD274 and gastric cancer: For gastric cancer, the ATTRACTION-2 trial confirmed the efficacy of nivolumab, a human IgG4 monoclonal antibody, against PD-1 in patients with advanced gastric cancer after two or more lines of chemotherapy, regardless of PD-L1 expression [15].